Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma

NCT00022568 is registered in ClinicalTrials.gov with Herbert Irving Comprehensive Cancer Center as lead sponsor.

NCT NCT00022568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)